PARIS, Aug 3 (Reuters) – French drugmaker Sanofi (SASY.PA) said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio (TBIO.O), as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio.
The boards of both companies had approved the deal, the firm added.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Chief Executive Paul Hudson said.Reporting by Matthias Blamont and Sudip Kar-Gupta; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.
AiRE is designed to identify automated actors before funds move, while the evidence disclosed centers…
The restaurant-software company is pairing commercial leadership with global talent oversight, but disclosed no financial…
Dubai South tops of off-plan sales rankings for eighth month in a row Dubai, UAE,…
The banking software provider says its NVIDIA-powered platform can run across private cloud, managed cloud…
As multi-billion-dollar LNG projects advance toward FID and commissioning, Standard Bank and the Mozambique Oil…
Wes Shattler will lead two consulting offerings aimed at helping payments businesses organize compliance governance…